What is the appropriate intramuscular (IM) dose of furosemide (Bumex) for an adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bumetanide IM Dosing

For intramuscular administration of bumetanide (Bumex), the initial dose is 1.0 mg, with a maximum single dose of 4 to 8 mg 1, 2, 3.

Dosing Guidelines

The FDA-approved drug label and multiple ACC/AHA heart failure guidelines consistently specify the following IM dosing parameters 4:

  • Initial dose: 1.0 mg IM
  • Maximum single dose: 4-8 mg
  • Frequency: Can be given once to three times daily if needed
  • Route equivalence: IM and IV bumetanide produce almost equal diuretic responses 4

Clinical Context for IM Administration

IM bumetanide should be used when gastrointestinal absorption is impaired or oral administration is not practical 4. The parenteral route (IM or IV) is appropriate when:

  • Intestinal edema reduces oral bioavailability
  • Patient cannot take oral medications
  • Rapid diuresis is needed but IV access is problematic

Dose Conversion Considerations

When converting from oral furosemide, bumetanide can be substituted at approximately a 1:40 ratio (1 mg bumetanide = 40 mg furosemide) 4. This is particularly relevant for patients with furosemide allergy, as cross-sensitivity is rare.

Important Safety Considerations

Monitor electrolytes closely, as bumetanide is 40-60 times more potent than furosemide on a milligram basis 4. Key monitoring includes:

  • Daily electrolytes (potassium, magnesium, sodium)
  • Renal function (creatinine, BUN)
  • Volume status and blood pressure
  • Ototoxicity risk increases with high doses, especially with renal impairment or concurrent aminoglycosides 4

Transition to oral therapy as soon as the patient can tolerate it 1, as parenteral administration should be temporary.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.